RxDoctor Payments Data

Kristin Schmid Biggerstaff, MD

Ophthalmology · Overland Park, KSNPI 1558590034

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Alcon at 47.5% of the total.

$2,774in general payments, 2019–2025

Across 105 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$450
  • Sun Pharmaceutical Industries Inc.$278
  • Bausch & Lomb Americas Inc.$171
  • Tarsus Pharmaceuticals, Inc.$169
  • NEW World Medical,inc.$72
  • plus $315 from 11 others

What the payments were for

  • Food & beverage$2,74399%
  • Other$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,774 in reported general payments places this provider in the 70th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$394,856
Medicare patients
932
Services billed
3,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$45,015
LumiganBimatoprost78$40,984
RhopressaNetarsudil Mesylate87$35,373
Travoprost98$13,547
Latanoprost1,415$11,906
SimbrinzaBrinzolamide/Brimonidine Tart43$10,817
IyuzehLatanoprost/Pf24$9,278
Cyclosporine11$8,387
RocklatanNetarsudil Mesylat/Latanoprost19$7,969
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat409$7,276
Dorzolamide-TimololDorzolamide/Timolol/Pf71$6,814
Brimonidine Tartrate147$6,616
CombiganBrimonidine Tartrate/Timolol15$6,298
Alphagan PBrimonidine Tartrate23$6,156
TafluprostTafluprost/Pf30$5,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$450$98,453159 claims
AlconSimbrinza$1,319$10,81743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →